Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570436 · ClinicalTrials.gov registry record · Phase 4
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
A Phase 4 study, sponsored by Viatris Specialty.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT04570436 is a Phase 4 study that has completed, run by Viatris Specialty. The registered enrollment target is 52 participants.
The verdict
NCT04570436, a Phase 4 study, has completed, sponsored by Viatris Specialty.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.
Interventions
- OTHER placebo
- DRUG gabapentin 600 mg
- DRUG gabapentin 1200 mg
- DRUG gabapentin 1800 mg
- DRUG diazepam 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04570436
The ClinicalTrials.gov registry entry for NCT04570436 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Specialty, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT04570436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04570436 about?
NCT04570436 is a clinical study titled "Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience". This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.
What is the current status of trial NCT04570436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2021-03-29. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT04570436?
The interventions under investigation include: placebo (OTHER), gabapentin 600 mg (DRUG), gabapentin 1200 mg (DRUG), gabapentin 1800 mg (DRUG), diazepam 20 mg (DRUG).
Who is sponsoring clinical trial NCT04570436?
This trial is sponsored by Viatris Specialty, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.